- Home
- VSTM vs CLYM Comparison
VSTM vs CLYM Comparison
Compare VSTM & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- CLYM
- Stock Information
- Founded
- VSTM 2010
- CLYM 2018
- Country
- VSTM United States
- CLYM United States
- Employees
- VSTM N/A
- CLYM N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- VSTM Health Care
- CLYM
- Exchange
- VSTM Nasdaq
- CLYM NYSE
- Market Cap
- VSTM 425.9M
- CLYM 86.5M
- IPO Year
- VSTM 2012
- CLYM 2021
- Fundamental
- Price
- VSTM $4.34
- CLYM $1.22
- Analyst Decision
- VSTM Strong Buy
- CLYM Buy
- Analyst Count
- VSTM 9
- CLYM 1
- Target Price
- VSTM $12.63
- CLYM $10.00
- AVG Volume (30 Days)
- VSTM 2.2M
- CLYM 403.6K
- Earning Date
- VSTM 08-07-2025
- CLYM 08-13-2025
- Dividend Yield
- VSTM N/A
- CLYM N/A
- EPS Growth
- VSTM N/A
- CLYM N/A
- EPS
- VSTM N/A
- CLYM N/A
- Revenue
- VSTM $10,000,000.00
- CLYM N/A
- Revenue This Year
- VSTM $129.06
- CLYM N/A
- Revenue Next Year
- VSTM $306.32
- CLYM N/A
- P/E Ratio
- VSTM N/A
- CLYM N/A
- Revenue Growth
- VSTM N/A
- CLYM N/A
- 52 Week Low
- VSTM $2.10
- CLYM $1.05
- 52 Week High
- VSTM $9.10
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- VSTM 26.56
- CLYM N/A
- Support Level
- VSTM $4.01
- CLYM N/A
- Resistance Level
- VSTM $6.62
- CLYM N/A
- Average True Range (ATR)
- VSTM 0.29
- CLYM 0.00
- MACD
- VSTM -0.11
- CLYM 0.00
- Stochastic Oscillator
- VSTM 9.17
- CLYM 0.00
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.